vialaudit
EPITALON·INDIANA·LAST CHECKED 1 NOV 2026

Is Epitalon legal in Indiana?

CAVEATS APPLY

Since 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board. This matters if FDA later allows pharmacies to compound Epitalon: in Indiana the ingredient could not be research grade. Federally: Not as a drug. Epitalon has no FDA approval, so selling it for human use breaks federal drug law, and a 'research use only' label does not protect a seller whose site signals human use. It is not a controlled substance, and possessing it is not a federal crime. Under an interim HHS policy of 28 October 2026, a licensed pharmacy may compound it against a prescription, by set routes and under strict conditions, without federal enforcement. That policy does not cover research-use-only vials sold online.

CATEGORY · NO APPROVAL

Full status breakdown

FEDERAL · STATE · SPORT-BODY

Federal status

FDA approval
no approval
DEA scheduling
not scheduled
503A compounding
FDA interim category: Nominated but withdrawn (off Category 2, not eligible)
503A Bulks List: pcac recommended
HHS interim policy (Oct 28, 2026): no enforcement against licensed 503A compounding with a prescription · routes: subcutaneous or intramuscular, in intermittent courses (acetate) · FEDERAL REGISTER ↗
Still not on the 503A Bulks List and not an approved drug. Removed from Category 2 on 15 Apr 2026. On 24 Jul 2026 the PCAC recommended it for the Bulks List (insomnia). On 28 Oct 2026 HHS issued an interim 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances' (Federal Register 30 Oct 2026, 91 FR 68526). HHS says it does not intend to take enforcement action against a state-licensed pharmacy, Federal facility or licensed physician compounding Epitalon against a patient-specific prescription, limited to subcutaneous or intramuscular, in intermittent courses, as a single ingredient, from API made by an FDA-registered facility with a full certificate of analysis. The Federal Register notice calls the policy a draft that is not binding; comments close 13 Nov 2026 (docket HHS-OASH-2026-0496). It does not cover 503B outsourcing facilities or research-use-only vials sold online.
PCAC review history
  • Jul 24, 2026 · recommended · recommended; reports differ on the margin (7-4-1 or 7-5-1) · SOURCE ↗
FDA Warning Letters
none on record for this compound
Shortage status
not currently on shortage list
Sale framing
Research-use-only posture: Unapproved; FDCA applies. July 2026 PCAC vote is the inflection point.
Personal possession: Not federally criminalized.

Indiana — state-specific

compounding restriction · Indiana

Since 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board. This matters if FDA later allows pharmacies to compound Epitalon: in Indiana the ingredient could not be research grade.

Sport-body status

WADA 2026
prohibited · class S0 · in and out of competition
Not named. S0 covers any pharmacological substance with no current approval by any government for human therapeutic use, and we found no such approval. WADA's 2027 List, in force from 1 Jan 2027, now names 'peptides' among the S0 examples; the status does not change.
USADA
NCAA
unknown

What we couldn’t verify

Also known as

4 ALIASES

Epitalon is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):

  • Epithalon
  • Ala-Glu-Asp-Gly
  • AEDG peptide
  • Khavinson tetrapeptide

Related

FOLLOW-ONS

Epitalon: US status, sources and what changed

THE ROUNDUP · MONTHLY

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 SUBSCRIBERS·0 SPONSORED ITEMS·11 ISSUES SINCE LAUNCH